high at the end of therapy. Suppressor cells normalized faster, whereas helper cell levels remained abnormally low for a long period. Most children became nonimmune to polio, whereas the majority had antibodies to measles, mumps, and rubella. Despite depressed immunity, serious infections were not documented. 
SCREENING NEWBORNS FOR SICKLE CELL

INTRODUCTION:
Screening of newborns for sickle cell disease (SCD) allows early initiation of prophylactic therapy, parental education, and comprehensive management, which results in reduced mortality. Since April 1993, a demonstration project to develop and implement a program of newborn screening for SCD has been conducted in Kumasi, Ghana, by the Comprehensive Sickle Cell Center at the Children's Hospital of Philadelphia in collaboration with the Ministry of Health and other institutions in Ghana. OBJECTIVE: Our goal was to assess the program of screening and follow-up of children with SCD in Ghana. METHODS: Infants are screened at birth or at wellinfant visits within days or a few weeks after birth. Mothers are asked to come for results within 4 weeks, and failing that, an extensive tracking system is used to deliver results to the homes of families with infants with possible SCD. Tracking relies solely on information obtained from mothers at the time of screening. The goal is to enroll infants with possible SCD into the sickle cell clinic by 8 weeks of age. Pregnant women, parents with children, and the general public are educated regularly about the screening program. Children with SCD receive comprehensive care through the Sickle Cell Clinic at Komfo Anokye Teaching Hospital (Kumasi, Ghana). RESULTS: From February 13, 1995 (when newborn testing was started), to December 31, 2005, a total of 202 244 infants were screened through 8 public health institutions and 14 private clinics in Kumasi and 1 private maternity center and 1 public health Center in Tikrom, a nearby, rural community. A total of 3745 (1.9%) infants were identified as having possible SCD with the following hemoglobin phenotypes according to isoelectric focusing: 2047 (1.04%) fetal sickle cell hemoglobin; 1684 (0.83%) fetal SC hemoglobin; and, 14 (0.003%) fetal SA hemoglobin (Table 1) . 
METHODS:
Since 1998, the Late Effects Surveillance System (LESS) of the German Society for Pediatric Oncology and Hematology has prospectively registered late effects in patients of all ages with relapse-free bone and soft tissue sarcoma in Austria, Germany, and Switzerland. The follow-up is conducted locally in accordance with LESS guidelines. Data are reported to the LESS center for collation and analysis. RESULTS: There were 67 patients available for analysis (42 male, 25 female) with a median age at diagnosis of 13 years and a median follow-up of 3.5 years. Registration had to be terminated for 17 patients as a result of relapse. In total, 43.3% (29 of 67) of the patients were reported to have at least 1 sequelae of treatment. Sixteen patients suffered toxicity in 1 organ system, 9 patients developed toxicity in 2 organ systems, and there were 3 organ systems affected in 4 patients. Nephrotoxicity was reported in 10.4% (7 of 67), cardiotoxicity in 8.9% (6 of 67), peripheral polyneuropathy in 5.9% (4 of 67), and other toxicities in 34.3% (23 of 67) of the patients. CONCLUSIONS: Sequelae of treatment for Ewing sarcoma within this cohort of the EICESS-92 study were not more frequent than reported previously. Patients are at risk for the development of several toxicities after treatment for Ewing sarcoma, and they should receive adequate medical follow-up. Ten patients rejected the graft. Eight received another transplant from the same donor, 7 of which were successful. Four patients died; causes of death were graftversus-host disease (GVHD) (2), disseminated toxoplasmosis (1), and brain hemorrhage (1). At a median follow-up time of 6.5 years, 84 of 88 children survived, 81 were cured and free from transfusions, and 3 remained transfusion-dependent. Severe acute GVHD developed in 18 children, and chronic GVHD developed in 8 patients. The overall survival rate, event-free survival rate, rejection rate, and transplant-related mortality rate were 95%, 94%, 11%, and 5%, respectively. Event-free survival was 100% for class I, 95% for class II, and 87% for class III. Eleven children had mixed chimera (residual recipient hematopoiesis) with normal levels of hemoglobin. CONCLUSIONS: HSCT is a highly effective treatment for thalassemic patients who have a fully matched donor (related or unrelated). Younger age at transplant secures excellent results with reduced morbidity and mortality rates.
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